Results 221 to 230 of about 111,477 (307)
Objective Rituximab, a CD20+ B cell depletion therapy, is frequently used to treat systemic lupus erythematosus (SLE). However, variability in patient response highlights the need for a deeper understanding of the underlying immune cell dynamics of B cell depletion and repopulation.
Haerin Jang +9 more
wiley +1 more source
CNS1-dependent regulatory T cells shape recovery from acute lung injury. [PDF]
McCullough MJ +12 more
europepmc +1 more source
Objective Regeneration and expansion of Treg by low‐dose interleukin‐2 (IL‐2) therapy is considered a potential treatment strategy for a wide range of autoimmune diseases. To provide a pathophysiologically‐based rationale for low‐dose IL‐2 therapy, we investigated whether reversible defects in the Treg–IL‐2 axis emerge in inflammatory myopathies ...
Justus Ohmes +10 more
wiley +1 more source
Impaired suppressive effect of FoxP3 regulatory T cells on B cells in multiple sclerosis. [PDF]
Greeck VB +11 more
europepmc +1 more source
Objective Identification of osteoarthritis (OA)–specific synovial inflammatory pathways and their temporal relevance is critical for therapeutic targeting. We compared mononuclear inflammatory/immune cell responses following joint injury that does or does not lead to OA to define bona fide OA‐associated cellular events.
Babak Moradi +10 more
wiley +1 more source
The role of impaired bone marrow Tregs in hematopoietic stem cell depletion for pediatric aplastic anemia probably involves immune privilege. [PDF]
Huang C +7 more
europepmc +1 more source
Objective We aimed to characterize CD4+ T cell plasticity in human systemic lupus erythematosus (SLE) by leveraging T cell receptor (TCR) repertoire features as markers of prior lineage states, integrating TCR and transcriptomic profiling to delineate plasticity patterns and evaluate their association with clinical disease activity. Methods We used TCR
Yasuo Nagafuchi +11 more
wiley +1 more source
First-in-human, phase 1, open-label study of alomfilimab, an anti-ICOS antibody, as a single agent and in combination with anti-PD-L1 in advanced malignancies. [PDF]
Naing A +15 more
europepmc +1 more source
T cells, the Next Big Target in Axial Spondyloarthritis?
Axial spondyloarthritis (axSpA) is a chronic inflammatory disease characterized by complex immune dysregulation, with T cells playing a central role in its pathogenesis. In this review, we synthesize current knowledge on diverse T cell subsets in axSpA, their pathogenic mechanisms, and emerging therapeutic strategies targeting these cells. We highlight
Mansi K. Aparnathi, Nigil Haroon
wiley +1 more source
Rapamycin-modified novel tolerogenic dendritic cells induce liver graft tolerance through MHC-II+CD8+ regulatory T cells. [PDF]
Zhou L +11 more
europepmc +1 more source

